Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

201975 citationsJournal Articlegreen Open Access

Authors

Jennifer Kimberly Lue

Sathyen A. Prabhu

Yuxuan Liu

Yulissa Gonzalez

Akanksha Verma

Prabhjot S. Mundi · Columbia University Irving Medical Center

Abstract

Inhibition of EZH2 and HDAC is synergistic and leads to the dissociation of PRC2 complex. Our findings support the clinical translation of the combination of EZH2 and HDAC inhibition in EZH2 dysregulated lymphomas.

Topics & Keywords

Epigenetics and DNA Methylation Histone Deacetylase Inhibitors Research Lymphoma Diagnosis and Treatment

Publication Details

Published in: Clinical Cancer Research

Volume 25, Issue 17, pp. 5271-5283

DOI: 10.1158/1078-0432.ccr-18-3989

Field-Weighted Citation Impact: 3.92

Command Palette

Precision Targeting with EZH2 and HDAC Inhibitors in Epigenetically Dysregulated Lymphomas

Authors

Abstract

Topics & Keywords

Publication Details